AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01279577
Drug: Medium dose TSO
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose TSO suspension
Trial: NCT01279577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT01077843
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cox-2 inhibitor
Trial: NCT01077843
Drug: Other Non-selective NSAIDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective NSAID
Trial: NCT01251809
Drug: PEG-rASNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500, 1000 or 1500 U/m2 BSA single infusion
Trial: NCT00844922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01081912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, no active substance, shells identical to active comparator capsules
Trial: NCT02919436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-filled capsules identical to active drug
Trial: NCT02950805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a placebo in either period 1 or period 2 by inhalation.
Trial: NCT02950805
Drug: AZD5634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
Trial: NCT02459795
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00183274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six month intervention with placebo drug
Trial: NCT02062489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2#/day, PO, daily
Trial: NCT02265770
Drug: VEC + HD-MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
Trial: NCT02265770
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
Trial: NCT01560767
Drug: peri-articular infiltration
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
Trial: NCT01152710
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
Trial: NCT03048903
Drug: Rheum Palmatum Root
RxNorm normalized name: RHEUM PALMATUM ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
Trial: NCT01370317
Drug: MK-1029
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Trial: NCT01370317
Drug: Placebo for MK-1029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Trial: NCT02709564
Drug: placebo 400 sublingual
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
Trial: NCT00543426
Drug: Fuzheng Huayu Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet,three times a day,four tablets one time
Trial: NCT00543426
Drug: sham Fuzheng Huayu Tablets (placebo)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, three times a day, four tablets one time
Trial: NCT00567320
Drug: Sugar pill or Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03610035
Drug: NPT189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Trial: NCT03610035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01181700
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00241939 300 ug using inhaler A
Trial: NCT01181700
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00241939 300 ug using inhaler A
Trial: NCT01181700
Drug: Treatment G
RxNorm normalized name: VanaLice Lice Killing Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00241939 300 ug using inhaler B
Trial: NCT01318551
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, 20 mg
Trial: NCT02716987
Drug: [18F]PGM299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]PGM299 injection
Trial: NCT01318551
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, 40 mg (optional)
Trial: NCT01318551
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, 80 mg (optional)
Trial: NCT01394627
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg x 2
Trial: NCT01394627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04744207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, once daily for 4 weeks
Trial: NCT03875235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Trial: NCT03965091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
Trial: NCT03559491
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term release steroid injection
Trial: NCT00117598
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day
Trial: NCT01108146
Drug: Arm 1 Hydrocortisone 10 mg
RxNorm normalized name: hydrocortisone 1 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone
Trial: NCT01108146
Drug: Arm 2 Hydrocortisone 30 mg
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo
Trial: NCT00202722
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous patient controlled analgesia (ivpca) during labour
Trial: NCT02025907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule taken orally (by mouth) once daily.
Trial: NCT00356928
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg/day intravenously (IV) on Days -2 and -1.
Trial: NCT02651584
Drug: CAM2038 SC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02651584
Drug: SL BPN/NX tabs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02651584
Drug: placebo SC injections
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02651584
Drug: SL placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00593463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
Trial: NCT01275469
Drug: GFT505 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
Trial: NCT01275469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
Trial: NCT02826642
Drug: IDH305
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02725723
Drug: epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00177333
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00769184
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day
Trial: NCT00769184
Drug: LCD
RxNorm normalized name: MGlcDAG (1->2) glucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day
Trial: NCT04001621
Drug: Pyrotinib combined with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
Trial: NCT01776515
Drug: Tramadol hydrochloride/Acetaminophen Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01776515
Drug: Tramadol hydrochloride/Acetaminophen SR Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02445807
Drug: DFD06-Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical application for 14 days.
Trial: NCT03821155
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone
Trial: NCT02445807
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical application for 14 days.
Trial: NCT04304716
Drug: Regional Anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
Trial: NCT01825707
Drug: [14C]-YH4808 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-YH4808 200 mg (oral) on day1
Trial: NCT02424253
Drug: ZPL-3893787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPL-3893787
Trial: NCT02424253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT01897454
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01897454
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03179332
Drug: Fiasp®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Trial: NCT03179332
Drug: Novorapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Trial: NCT00094978
Drug: Depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02598661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat sodium-matching placebo IV infusion.
Trial: NCT01972490
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
Trial: NCT01839279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04430985
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 each cycle: 400 mg/m2 i.v.
Trial: NCT00573417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05256147
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient will receive ibuprofen 400 mg before the phototherapy session.
Trial: NCT02502578
Drug: CNT-01 500 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
Trial: NCT02788240
Drug: Peg GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02788240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02195583
Drug: Sodium fluoride (1426 ppm) + zinc base A
RxNorm normalized name: sodium fluoride Oral Solution [Fluor a Day]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
Trial: NCT03045562
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
Trial: NCT02195583
Drug: Sodium fluoride (1426 ppm) + zinc base B
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
Trial: NCT04289532
Drug: 99mTc-RWY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
Trial: NCT00231829
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01783561
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
Trial: NCT01367535
Drug: SC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03872128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00840073
Drug: Mavik® 4 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 4 mg, single-dose fed
Trial: NCT02648438
Drug: AZD7594 Oral suspension (1200 μg oral formulation)
RxNorm normalized name: Guiadrine G-1200 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
Trial: NCT02648438
Drug: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
Trial: NCT02648438
Drug: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
Trial: NCT02648438
Drug: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
Trial: NCT02210195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 8 weeks.
Trial: NCT00917150
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of placebo, once daily for 24months
Trial: NCT02074020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once per week
Trial: NCT01372345
Drug: CIPRO®XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Trial: NCT00554502
Drug: supportive therapy with: ACE-inhibitor / ARB / Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.
Trial: NCT02491905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00554502
Drug: supportive and immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice
Trial: NCT02302976
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01422109
Drug: YH14659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH14659 capsule by oral
Trial: NCT03278470
Drug: HL237
RxNorm normalized name: Hydrocodone/Levorphanol 237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT03278470
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with same properties except for active ingredient
Trial: NCT03708458
Drug: indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
Trial: NCT04391595
Drug: LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Trial: NCT03206008
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02045472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00644774
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 ml of cherry flavored oral suspension 100 mg/5 ml